NCT00291226View on ClinicalTrials.gov

Glycine vs Placebo for the Schizophrenia Prodrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Schizophrenia Prodrome
Interventions
DRUG

Glycine

Glycine 0.4 g/kg bid

DRUG

Placebo

Placebo

Trial Locations (1)

06519

PRIME Clinic, New Haven

Sponsors

Collaborators (1)

Glytech, Inc
All Listed Sponsors
collaborator

Glytech, Inc

INDUSTRY

collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

Yale University

OTHER

NCT00291226 - Glycine vs Placebo for the Schizophrenia Prodrome | Biotech Hunter | Biotech Hunter